Wilex AG has announced the appointment of Jan Schmidt-Brand to the position of chief financial officer, effective 1 September 2012. He will replace Peter Llewellyn-Davies, who is leaving his position after six years and will act as an advisor to the company.
Dr Schmidt-Brand is currently the managing director of Wilex’s wholly-owned subsidiary, Heidelberg Pharma GmbH. Prior to this, he was managing director of the Austrian BASF-Pharma subsidiary, EBEWE Arzneimittel GmbH.
Dr Schmidt-Brand is a member of the board of BioDeutschland and head of that organisation’s finance and tax working group.
Wilex announced the appointment on 7 August 2012.
Copyright 2012 Evernow Publishing Ltd